Stepwise Synthesis of [Ru(trpy)(L)(X)]<i>ⁿ</i>⁺ (trpy = 2,2‘:6‘,2‘ ‘-Terpyridine; L = 2,2‘-Dipyridylamine; X = Cl^-, H₂O, NO₂<... by Nripen Chanda (1761028)

“…The electron−proton content of the redox process over the pH range of 6.8−1.0 was calculated to be a 2e^-/1H⁺ process. However, the chemical oxidation of <b>2</b> by an aq Ce(IV) solution in 1 N H₂SO₄ led to the direct formation of corresponding oxo species [Ru^IV(trpy)(L)(O)]²⁺ via the concerted 2e^-/2H⁺ oxidation process. …”

Stepwise Synthesis of [Ru(trpy)(L)(X)]<i>ⁿ</i>⁺ (trpy = 2,2‘:6‘,2‘ ‘-Terpyridine; L = 2,2‘-Dipyridylamine; X = Cl^-, H₂O, NO₂<... by Nripen Chanda (1761028)

“…The electron−proton content of the redox process over the pH range of 6.8−1.0 was calculated to be a 2e^-/1H⁺ process. However, the chemical oxidation of <b>2</b> by an aq Ce(IV) solution in 1 N H₂SO₄ led to the direct formation of corresponding oxo species [Ru^IV(trpy)(L)(O)]²⁺ via the concerted 2e^-/2H⁺ oxidation process. …”

Stepwise Synthesis of [Ru(trpy)(L)(X)]<i>ⁿ</i>⁺ (trpy = 2,2‘:6‘,2‘ ‘-Terpyridine; L = 2,2‘-Dipyridylamine; X = Cl^-, H₂O, NO₂<... by Nripen Chanda (1761028)

“…The electron−proton content of the redox process over the pH range of 6.8−1.0 was calculated to be a 2e^-/1H⁺ process. However, the chemical oxidation of <b>2</b> by an aq Ce(IV) solution in 1 N H₂SO₄ led to the direct formation of corresponding oxo species [Ru^IV(trpy)(L)(O)]²⁺ via the concerted 2e^-/2H⁺ oxidation process. …”

Stepwise Synthesis of [Ru(trpy)(L)(X)]<i>ⁿ</i>⁺ (trpy = 2,2‘:6‘,2‘ ‘-Terpyridine; L = 2,2‘-Dipyridylamine; X = Cl^-, H₂O, NO₂<... by Nripen Chanda (1761028)

“…The electron−proton content of the redox process over the pH range of 6.8−1.0 was calculated to be a 2e^-/1H⁺ process. However, the chemical oxidation of <b>2</b> by an aq Ce(IV) solution in 1 N H₂SO₄ led to the direct formation of corresponding oxo species [Ru^IV(trpy)(L)(O)]²⁺ via the concerted 2e^-/2H⁺ oxidation process. …”

Pharmacologic control of oxidative stress and inflammation determines whether diabetic glomerulosclerosis progresses or decreases: A pilot study in sclerosis-prone mice - Fig 2 by Fabrizio Grosjean (352916)

Increased NFKB2⁺ cells and decreased ACADM⁺ and ANGPTL4⁺ cells were observed in KIRC tissues. by Yu Zhang (12946)

“…KIRC tissues from the local hospital showed increased NFKB2+ cells compared to paracarcinoma tissues. B-E. …”

IL–1β levels and IL–18 expression are markedly decreased in the MyD88^-/- and TLR2^-/- mice. by Deysi V. T. Wong (803817)

AQP2 and p-AQP2 IMCD localization. by Sophie Constantin Lütken (689916)

Scatter plot of differential gene expression values upon E/R KD in two cell lines. by Gerhard Fuka (200028)

“…<p>Each dot represents the mean regulation value (log2-fold change of E/R-repressed versus control cells) of three and two replicas, for REH and AT-2 cell lines, respectively. x-axis: REH cell line, y-axis: AT-2 cell line. …”

Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides by Zufang Ba (11036420)

“…Developing a straightforward and effective strategy to modify antimicrobial peptides (AMPs) is crucial in overcoming the challenges posed by their instability and toxicity. …”

Fibrin concentration of 10,000 simulations compared to experimental data of blood clotting over collagen/ TF under venous flow rate. by Jason Chen (15937)

Structure–Activity Studies of 1<i>H</i>‑Imidazo[4,5‑<i>c</i>]quinolin-4-amine Derivatives as A₃ Adenosine Receptor Positive Allosteric Modulators by Lucas B. Fallot (14106171)

“…Although having low Caco-2 permeability and high plasma protein binding, hydrophobic 2-cyclohept-4-enyl-<i>N</i>-3,4-dichlorophenyl, MRS7788 <b>18</b>, and 2-heptan-4-yl-<i>N</i>-4-iodophenyl, MRS8054 <b>39</b>, derivatives were orally bioavailable in rat. 2-Heptan-4-yl-<i>N</i>-3,4-dichlorophenyl <b>14</b> and 2-cyclononyl-<i>N</i>-3,4-dichlorophenyl <b>20</b> derivatives and <b>39</b> greatly enhanced Cl-IB-MECA-stimulated [³⁵S]GTPγS binding <i>E</i>_max, with only <b>12b</b> trending toward decreasing the agonist EC₅₀. …”

Structure–Activity Studies of 1<i>H</i>‑Imidazo[4,5‑<i>c</i>]quinolin-4-amine Derivatives as A₃ Adenosine Receptor Positive Allosteric Modulators by Lucas B. Fallot (14106171)

“…Although having low Caco-2 permeability and high plasma protein binding, hydrophobic 2-cyclohept-4-enyl-<i>N</i>-3,4-dichlorophenyl, MRS7788 <b>18</b>, and 2-heptan-4-yl-<i>N</i>-4-iodophenyl, MRS8054 <b>39</b>, derivatives were orally bioavailable in rat. 2-Heptan-4-yl-<i>N</i>-3,4-dichlorophenyl <b>14</b> and 2-cyclononyl-<i>N</i>-3,4-dichlorophenyl <b>20</b> derivatives and <b>39</b> greatly enhanced Cl-IB-MECA-stimulated [³⁵S]GTPγS binding <i>E</i>_max, with only <b>12b</b> trending toward decreasing the agonist EC₅₀. …”

Graphic representation of the definition of the index of variation of intracycle velocity (VIV_Index). by Marek Rejman (9199616)

Nrf2-regulated antioxidant protein NQO1 expression is decreased in lung lesions from <i>M. tuberculosis</i> infected guinea pigs. by Gopinath S. Palanisamy (200914)

Advancing the science of NOWS research. by Sarah E. Maylott (14560785)

“…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”

Protocol measures. by Sarah E. Maylott (14560785)

“…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”

Cry variables. by Sarah E. Maylott (14560785)

“…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”

Delphinidin alters VEGF-A splicing to increase VEGF-A₁₆₅b and decrease total VEGF-A expression. by Megan Stevens (3964886)

Significances of Tukey-HSD post-hoc tests for the group mean difference of the normalized maximal torques (lower left corner shaded in grey) in the knee extensors (KE), the hip abd... by Franziska Daun (6433328)